Thermo Fisher highlights proteomics at HUPO 2021

By The Science Advisory Board staff writers

November 15, 2021 -- Thermo Fisher Scientific plans to highlight its proteomics solutions and collaboration with industry experts at the virtual Human Proteome Organization Reconnect 2021 meeting.

Proteomics research shows promise for discovering new biomarkers for disease diagnosis, the company said. Thermo Fisher is extending its co-marketing agreement with Biognosys for that company's PQ500 Reference Peptide Kit, which can quantify more than 500 proteins in human plasma/serum samples and can be used with Thermo Scientific's Orbitrap Exploris 480 mass spectrometer.

Thermo Fisher will also highlight its Thermo Scientific Vanquish Neo Ultra-High Performance Liquid Chromatography system, which works with Orbitrap for proteomics analyses.

Finally, the company has boosted its chromatography offerings through the purchase of PharmaFluidics, a μPAC microchip-based chromatography column developer, and has brokered another expanded co-marketing agreement with Cellenion, a single-cell sample preparation developer.

3M, Thermo Fisher collaboration combines technologies
3M Separation and Purification Sciences announced a global agreement with Thermo Fisher Scientific that allows biopharmaceutical manufacturers to pair...
Thermo Fisher reports revenue boost in Q3
Thermo Fisher Scientific reported a 9% increase in revenue for the third quarter of 2021, although its net income slipped slightly. The company saw its...
Thermo Fisher unveils new NK cell culture medium
Thermo Fisher Scientific has introduced Gibco Cell Therapy Systems NK-Xpander Medium, a new cell culture medium that supports the large-scale growth and...
Thermo Fisher opening new biologics site in Switzerland
Thermo Fisher Scientific recently assumed operational responsibility for a new biologics manufacturing site in Lengnau, Switzerland, the company announced.
Thermo Fisher seeks grant proposals that leverage NGS
Thermo Fisher Scientific is accepting new proposals that leverage next-generation sequencing (NGS) for its Oncomine Clinical Research Grant.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter